title: Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story?
authors.affiliation: Divisions of 1Gastroenterology, Department of Medicine, University of California, San Francisco, CA.
authors.forename: Neil
authors.initials: N
authors.lastname: Mehta
authors.affiliation: 2Transplantation, Department of Surgery, University of California, San Francisco, CA.
authors.forename: John P
authors.initials: JP
authors.lastname: Roberts
authors.affiliation: Divisions of 1Gastroenterology, Department of Medicine, University of California, San Francisco, CA.|2Transplantation, Department of Surgery, University of California, San Francisco, CA.
authors.forename: Francis Y
authors.initials: FY
authors.lastname: Yao
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular; D006801:Humans; D008113:Liver Neoplasms; D016031:Liver Transplantation; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases
chemical_list: D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus